<DOC>
	<DOCNO>NCT01874470</DOCNO>
	<brief_summary>The purpose ALLEGRO-HTN trial evaluate safety effectiveness renal denervation subject resistant hypertension use Allegro renal denervation system</brief_summary>
	<brief_title>Renal Denervation Allegro System Patients With Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Age 18 65 year time randomization Stable medication regimen include 3 antihypertensive medication different class , include diuretic ( change minimum 4 week prior screen ) expect change least 6 month 1 ) Office SBP and/or DBP ≥160/100 mm Hg ( ≥ 150/95 mmHg type II diabetic patient ) , 2 ) ABPM 24 hour average SBP and/or DBP ≥140 and/or 90 mmHg Main renal artery ≥4 mm diameter ≥20 mm treatable length ( visual estimation ) eGFR≥45 mL/min/1.73 m2 Written inform consent Type 1 diabetes mellitus Secondary hypertension Has implantable cardioverter defibrillator ( ICD ) pacemaker Myocardial infarction , unstable angina pectoris , syncope , cerebrovascular accident within 6 month screen period Intravascular thrombosis unstable atherosclerotic plaque Has hemodynamically significant valvular heart disease Pregnant , nursing , plan pregnant Any serious medical condition may adversely affect safety participant study Currently enrol another investigational drug device trial Angiographic Renal artery stenosis ( ≥50 % ) renal artery aneurysm either renal artery History prior renal artery intervention include balloon angioplasty stenting Multiple renal artery main renal artery estimate supply &lt; 75 % kidney Main renal artery &lt; 4 mm diameter &lt; 20 mm treatable length ( visual estimation ) Renal artery abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>